Huntsman Cancer Institute

The Mountain West’s only NCI-Designated Comprehensive Cancer Center—Delivering a Cancer-Free Frontier™ through innovative research & world-class patient care.

[University of Utah @UUtah]

We are saddened by the loss of Karen Haight Huntsman.

She lived a life defined by compassion, generosity & an unwavering belief in the power of healing & hope. Alongside Jon & her family, she helped build one of the great philanthropic legacies.

📰 https://t.co/z8nTScAKn2

[Huntsman Cancer Institute @huntsmancancer]

Today, we honor the life of Karen Huntsman. She believed deeply in creating hope, comfort, and dignity for people facing cancer. Her kindness and generosity continue to touch lives every day, and her legacy will endure for generations. https://t.co/fOsXIfafuk

[Dr Joseph McCollom DO @realbowtiedoc]

The 👏👏👏 heard round the 🌎 #ASCO26

[Huntsman Cancer Institute @huntsmancancer]

A standing ovation at #ASCO26 for results that are bringing hope in pancreatic cancer research. The RASolute 302 trial increased median overall survival from 6.7 to 13.2 months. We were proud to be one of 60 sites offering this trial https://t.co/mDj8qoEbyG

📹 @realbowtiedoc

[Jessica Allen @JessicaAllenMD]

Honored to present our CUBIC study on real-world outcomes in bispecific antibodies in relapsed/refractory follicular lymphoma. In a cohort of 99 patients, these therapies appear similarly as safe and effective as demonstrated in clinical trial populations. Manuscript coming soon!

[Toni Choueiri, MD @DrChoueiri]

Live now #ASCO26 @asco with @neerajaiims !

Enza/Tala (ARPI/PARP inhibitor) vs Enza in HRR-deficient metastatic prostate cancer

Concomitant @NEJM paper

@OncoAlert

[Nicolas Sayegh, MD @nsayeghmd]

👉🏻 Happening now @ASCO #ASCO26 : results of the phase 3 TALAPRO-3 trial meeting its primary endpoint with significant rPFS benefit with TALA + ENZA over ENZA in HRR+ mHSPC. Benefit remains significant in BRCA and non-BRCA. @neerajaiims @Huntsman_GU @huntsmancancer

[Sumanta K. Pal, MD, FASCO @montypal]

Cheers to @neerajaiims on his presentation of the #TALAPRO3 data w simultaneous @NEJM publication! It reflects the dream of many clinical investigators in #oncology - to lead a trial & generate paradigm shifting data in a field that you have devoted your life to (in this case, #prostatecancer).

If you see him at #ASCO26, inquire about his remarkable story. At @huntsmancancer, he built the GU program from scratch into one of the highest performing programs worldwide. He did this over the span of nearly two decades through mentorship of his faculty & fellows (@umangtalking @maughanonc @ziremozay @ggebraelmd et al), extensive outreach to the local community & active participation & leadership in multiple studies (a mix of industry, ISTs & @SWOG). Simply amazing.

[Bogdana Schmidt MD, MPH @BogdanaSchmidt]

@neerajaiims is a remarkable clinician, educator, and mentor! @huntsmancancer @Huntsman_GU

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Breaking news #ASCO26 Adding Talazoparib to enzalutamide significantly ⬆️ rPFS 👉 HR 0.48 in pts w/ mCSPC (mAPMS) #prostatecancer w/ HRRm 👉 @NEJM paper https://t.co/HmXyNvbExi 👇 @ASCO @oncoalert @urotoday @PCF_Science @OpenMedicineHQ

[Huntsman Cancer Institute @huntsmancancer]

A Phase 3 clinical trial led by @neerajaiims, MD, FASCO, found that combining talazoparib and enzalutamide reduced the risk of disease progression or death by 52% in certain patients with metastatic prostate cancer. https://t.co/HjwJGoO0jr

[Huntsman Cancer Institute @huntsmancancer]

We were honored to join national cancer center leaders at a symposium focused on the future of cancer research and care. Discussions included rural cancer outcomes, innovation, and the growing role of microbiome science in prevention and treatment. https://t.co/y60HrBZrLc

[UofUHeme @UofUHematology]

Proud to share that Dr. Tsewang Tashi represented our Mastocytosis Center of Excellence at the American Initiative on Mast Cell Diseases (AIM) Annual Meeting on May 16–17 in Ann Arbor, MI, where he also chaired the session “Novel Therapeutics in Non-Advanced and Advanced SM.”

[UofUHeme @UofUHematology]

The University of Utah is pleased to share that Dr. Tsewang Tashi and Dr. Josef Prchal were invited speakers at MPN Asia 2026 on May 9 in Seoul, Korea, where they shared their expertise and engaged with colleagues advancing MPN research and patient care worldwide.

[KSL.com - Utah Breaking News @KSLcom]

The Huntsman Cancer Institute is doubling the capacity of its proton therapy center. It is the only location the therapy, used in brain cancers and children's cancers, is available in Utah.
https://t.co/k5hb39xq5D

[Huntsman Cancer Institute @huntsmancancer]

After a rare cancer diagnosis threatened her future, Morgan Marietti underwent treatment while holding onto hope for motherhood. Today, five years in remission, she’s found healing, purpose, and new meaning in becoming a parent https://t.co/fKI7SlfA1U

[Huntsman Cancer Institute @huntsmancancer]

We recently had the opportunity to welcome @theNCI Director Anthony Letai, MD, PhD, (@NCIDirector) for conversations about the future of cancer research, clinical trials, and expanding access to care for rural and frontier communities. https://t.co/vlHgCfaId2

[Huntsman Cancer Institute @huntsmancancer]

At 9 years old, Noah became our first pediatric patient treated in the newly opened Proton Therapy Center. Now cancer-free at 14, he returned to help break ground on our expansion, which will allow us to provide the same lifesaving care to more patients https://t.co/nCROScmcgz

[Adrienne Dorrance @Dorrance_Lab]

Dr.Luis Batista talks telomeres at the interstellar session of the Myeloid meeting @UofUHematology @huntsmancancer

[UofUSurgery @UofUSurgery]

In the Pediatric General Surgery Clinic at @primarychildren , a simple art commission became something more. After a cancer diagnosis, artist Zachary Proctor created a piece centered on empowerment. Read the full story: https://t.co/fwdZ72KmvR